99mTc-MIBI核素显像与CT在原发性甲状旁腺功能亢进症中的诊断价值

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the clinical value of 99mTc-sestamibi(MIBI) scintigraphy and CT in the diagnosis of primary hyperparathyroidism. Methods: Retrospectively analyzed the image features of 99mTc-MIBI and CT in 38 patients with primary hyperparathyroidism, which were confirmed by pathology. Comparison of the sensitivity of 99mTc-MIBI scintigraphy, CT, the combination of the two methods. Results: The sensitivity of 99mTc-MIBI, CT and the combined methods in diagnosis of primary hyperparathyroidism was 89.65%, 64.00% and 93.75% respectively. There were significant difference between 99mTc-MIBI and CT, CT and the combination group. The sensitivity of the combination group was superior to the other two methods. Conclusion: Both 99mTc-MIBI and CT provide important information for the pre-operation evaluation of primary hyperparathyroidism. 99mTc-MIBI in combination with CT can increase the accuracy of diagnosis of the primary hyperparathyroidism.

Key words： Hyperparathyroidism Technetium Tc 99m sestamibi Radionuclide imaging Tomography, X-ray computed

Received: 24 August 2015

PACS:	Ｒ582.1
	Ｒ817.4
	Ｒ814.42

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Zheng-guo
	LIU Qi-yu
	CHEN Jiao
	YANG Xing
	HE Yu

Cite this article:

CHEN Zheng-guo,LIU Qi-yu,CHEN Jiao, et al. The diagnostic value of 99mTc-sestamibi scintigraphy and CT in primary hyperparathyroidism[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(4): 239-242.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2016/V27/I4/239

[1]Taubman ML, Goldfarb M, Lew JI. Role of SPECT and SPECT/CT in the Surgical Treatment of Primary Hyperparathyroidism[J]. Int J Mol Imaging, 2011, 2011: 141593.
[2]Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?[J]. Cancer, 2007, 110(2): 255-264.
[3]Coakley AJ, Kettle AG, Well CP, et al. 99mTc sestamibi—a new agent for parathyroid imaging[J]. Nucl Mde Commun, 1989, 10(11): 791-794.
[4]Hetrakul N, Civelek AC, Stagg CA, et al. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria[J]. Surgery, 2001, 130(6): 1011-1018.
[5]Moralidis E. Radionuclide parathyroid imaging: a concise, updated review[J]. Hell J Nucl Med, 2013, 16(2): 125-133.
[6]Burke JF, Naraharisetty K, Schneider DF, et al. Early-phase technetium-99m sestamibi scintigraphy can improve preoperative localization in primary hyperparathyroidism[J]. Am J Surg, 2013, 205(3): 269-273.
[7]Schachter PP, Issa N, Shimonov M, et al. Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy[J]. Arch Surg, 2004, 139(4): 433-437.
[8]Noda S, Onoda N, Kashiwagi S, et al. Strategy of operative treatment of hyperparathyroidism using US scan and (99m)Tc-MIBI SPECT/CT[J]. Endoc J, 2014, 61(3): 225-230.
[9]Tokmak H, Demirkol MO, Alagol F, et al. Clinical impact of SPECT-CT in the diagnosis and surgical management of hyper-parathyroidism[J]. Int J Clin Exp Med, 2014, 7(4): 1028-1034.
[10]Pons F, Torregrosa JV, Fuster D. Biological factors influencing parathyroid localization[J]. Nucl Med Commun, 2003, 24(2): 121-124.
[11]Hayakawa N, Nakamoto Y, Kurihara K, et al. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia[J]. Nucl Med Commun, 2015, 36(1): 53-59.
[12]Chroustova D, Kubinyi J, Trnka J, et al. The role of 99mTc-MIBI SPECT/Low dose CT with 3D subtraction in patients with secondary hyperparathyroidism due to chronic kidney disease[J]. Endocr Regul, 2014, 48(2): 55-63.
[13]Taieb D, Hindie E, Grassetto G, et al. Parathyroid scintigraphy: when, how, and why? A concise systematic review[J]. Clin Nucl Med, 2012, 37(6): 568-574.
[14]Mancuso AA, Dillon WP. The Neck[J]. Radiol Clin North Am, 1989, 27(2): 407.
[15]Beland MD, Mayo-Smith WW, Grand DJ, et al. Dynamic MDCT for localization of occult parathyroid adenomas in 26 patients with primary hyperparathyroidism[J]. AJR, 2011, 196(1): 61-65.
[16]Solorzano CC, Carneiro-Plad. Minimizing cost and maximizing success in the preoperative localization strategy for primary hyperparathyroidism[J]. Surg Clin North Am, 2014, 94(3): 587-605.
[17]Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography[J]. Surgery, 2006, 140(6): 932-941.
[18]Kukar M, Platz TA, Schaffner TJ, et al. The use of modified four-dimensional computed tomography in patients with primary hyperparathyroidism: an argument for the abandonment of routine sestamibi single-positron emission computed tomography(SPECT)[J]. Ann Surg Oncol, 2015, 22(1): 139-145.
[19]Starker LF, Mahajan A, Bjorklund P, et al. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism[J]. Ann Surg Oncol, 2011, 18(6): 1723-1728.
[20]Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for SPECT/CT imaging 1.0[J]. J Nucl Med, 2006, 47(7): 1227-1234．
[21]Serra A, Bolasco P, Satta L, et al. Role of SPECT/CT in the preoperative assessment of hyperparathyroid patients[J]. Radiol Med, 2006, 11(7): 999-1008.